John O. DaSilva - Concepedia

Author

John O. DaSilva

Regeneron (United States)ORCID

Also Known As

J.O. DaSilva, John DaSilva, John O. DaSilva, John O. DaSilva

106

Publications

512

Citations

H-Index

Concepts

All Affiliations

Regeneron (United States)Progenics Pharmaceuticals (United States)State University of New York Stony Brook University University of Virginia

About

John O. DaSilva is an author at Regeneron (United States) specializing in medicine, cell biology, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	234
2	Natural Sciences	3	3	234
3	Cell Biology	3	3	234
4	Molecular Biology	2	2	156
5	Cellular Physiology	1	1	78

John O. DaSilva

Publications

498

Citations

H-Index

Page 1

	Year	Citations
hSpry2 Is Targeted to the Ubiquitin-Dependent Proteasome Pathway by c-Cbl Amy B. Hall, Natalia Jura, John O. DaSilva, Current Biology Protein FunctionUbiquitin-dependent Proteasome PathwayCell RegulationMedicineNatural Sciences	2003	139
Regulation of Sprouty Stability by Mnk1-Dependent Phosphorylation John O. DaSilva, Lizhong Xu, Hong Joo Kim, Molecular and Cellular Biology Signal TransductionDevelopmental BiologyMolecular PhysiologySprouty StabilityMedicine	2006	78
The Neuroendocrine-Derived Peptide Parathyroid Hormone–Related Protein Promotes Prostate Cancer Cell Growth by Stabilizing the Androgen Receptor John O. DaSilva, Daniel Gioeli, Michael J. Weber, Cancer Research	2009	59
Inhibition of Neurotensin Receptor 1 Selectively Sensitizes Prostate Cancer to Ionizing Radiation Nicholas C.K. Valerie, Eli V. Casarez, John O. DaSilva, Cancer Research	2011	48
Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC Seung Yeon Oh, You Won Lee, Eun Ji Lee, Clinical Cancer Research	2022	46
Neuroendocrine‐derived peptides promote prostate cancer cell survival through activation of IGF‐1R signaling John O. DaSilva, George P. Amorino, Eli V. Casarez, The Prostate	2012	41
A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade John O. DaSilva, Katie Yang, Oliver Surriga, Molecular Cancer Therapeutics	2021	40
A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models John O. DaSilva, Katie Yang, Andrés E. Perez Bay, Clinical Cancer Research	2019	30
A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes Andrés E. Perez Bay, Devon Faulkner, John O. DaSilva, Molecular Cancer Therapeutics Molecular BiologyExtracellular MicrovesiclesAnalytical UltracentrifugationImmunotherapyEndocytic Pathway	2023	17

Page 1